Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheap drugs may tame severe sun allergy

NCT ID NCT06476366

Disease control Sponsor: Pak Emirates Military Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested two older, low-cost drugs—methotrexate and azathioprine—against chronic actinic dermatitis, a painful skin reaction to sunlight. Fifty adults were randomly assigned to one drug for 24 weeks. Researchers tracked eczema severity and safety. The goal was to see if either drug could control the disease without steroids.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Methotrexate and azathioprine
What this could lead to
If one drug proves safer or more effective, it could become a standard, affordable treatment for chronic actinic dermatitis.
What could go wrong
This is a very small, early-phase trial (50 participants) from a single military hospital. Results may not apply to broader populations, and both drugs have known side effects like liver toxicity and bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

50 people

The number who actually took part.

Started

Jul 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All newly diagnosed as well as patients with an established diagnosis of CAD presenting to the outpatient department or the emergency department of PEMH or CMH will be included in the study. Exclusion Criteria: * Patients with coexisting conditions requiring immunosuppressants will be excluded from the study. Patients with dementia or any other neuropsychiatric disorder will also be excluded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic actinic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic actinic dermatitis photosensitivity disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic actinic dermatitis

Contacts and locations

Locations

  • Pak Emirates Military Hospital

    Rawalpindi, Punjab Province, Pakistan